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Abstract Homozygous familial hypercholesterolemia
(HoFH) is a rare, genetic disorder characterized by an
absence or impairment of low-density lipoprotein receptor
(LDLR) function resulting in significantly elevated low-
density lipoprotein cholesterol (LDL-C) levels. The
cholesterol exposure burden beginning in utero greatly
increases the risk for atherosclerotic cardiovascular disease
(ASCVD) and premature death. The genetic heterogeneity
of HoFH results in a wide range of LDL-C levels among
both untreated and treated patients. Diagnosis of HoFH
should, therefore, be based on a comprehensive evaluation
of clinical criteria and not exclusively LDL-C levels. As
treatment goals, the European Atherosclerosis Society and
International FH Foundation suggest target LDL-C levels of
\100 mg/dL (\2.5 mmol/L) in adults or \70 mg/dL
(\1.8 mmol/L) in adults with clinical coronary artery dis-
ease or diabetes. The National Lipid Association (NLA)
recommends that LDL-C levels be reduced to\100 mg/dL
(\2.5 mmol/L) or by at least C50 % from pretreatment
levels. Conventional therapy combinations that lower
atherogenic lipoproteins levels in the blood, such as statins,
ezetimibe, bile acid sequestrants and niacin, as well as
lipoprotein apheresis, are usually unable to reduce LDL-C
levels to recommended targets. Two recently approved
agents that reduce lipoprotein synthesis and secretion by
the liver are lomitapide, a microsomal triglyceride transfer
protein inhibitor, and mipomersen, an apolipoprotein B
antisense oligonucleotide. The newly approved inhibitor of
proprotein convertase subtilisin/kexin type 9 (PCSK9),
evolocumab, also shows promise for the management of
FH. Because of the extremely high risk for ASCVD, HoFH
patients should be identified early.
Key Points
HoFH is characterized by significantly elevated
LDL-C levels, which greatly increase the risk for
atherosclerotic cardiovascular disease and premature
death in untreated patients.
Conventional lipid-lowering therapy options, and
combinations of these agents, usually cannot
adequately reduce LDL-C levels in patients with
HoFH.
The recently approved agents lomitapide and
mipomersen as well as the inhibitor of proprotein
convertase subtilisin/kexin type 9 (PCSK9),
evolocumab, shows promise for HoFH management.
1 Introduction
Familial hypercholesterolemia (FH) is an autosomal co-
dominant disorder of lipoprotein metabolism that is charac-
terized by abnormally high levels of serum low-density
lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB)
containing lipoproteins [1–4]. Consequently, patientswith FH
are at an increased risk for cardiac events and early death from
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premature atherosclerotic cardiovascular disease (ASCVD).
Despite the substantial socioeconomic burden of cardiovas-
cular disease in these patients, FH continues to be severely
underdiagnosed and undertreated [2, 4, 5].
FH is caused by mutations in the LDL receptor (LDLR)
gene or other genes that affect LDLR function [1–3].
Patients with heterozygous FH (HeFH) carry a single
inherited copy of the mutant gene and have cholesterol
levels that are 2- to 3-fold higher than normal [2, 3, 6, 7].
Homozygous FH (HoFH), the more aggressive and rare
form of FH, results from two inherited mutant alleles of the
defective gene resulting in cholesterol levels that are 3- to
6-fold higher than normal [3].
HoFH is characterized by an absence or impairment in
LDLR itself or in pathways that regulate the uptake of
LDL-C [6, 7]. The physical signs of HoFH are generally
more severe and occur at an earlier age than in patients
with HeFH [1, 3, 6, 7], and untreated patients with HoFH
generally present with atherosclerosis, aortic valve disease,
and coronary heart disease before the age of 20 years [2, 5,
8]. The life-long exposure to profound hypercholes-
terolemia is directly responsible for vascular endothelial
damage and accelerated atherosclerosis, greatly increasing
the risk for premature coronary artery disease (CAD),
peripheral artery disease, and valvular disease, especially
aortic stenosis [5, 7]. The deposition of cholesterol in
vascular and extravascular compartments, such as tendons
and skin, results in xanthomas (Fig. 1) and the deposition
of lipid in the cornea of the eyes causes corneal arcus and
an increase in intraocular pressure [1]. Patients should be
identified early and provided aggressive interventions to
reduce the cumulative LDL-C burden [2, 5].
2 Prevalence of Homozygous Familial
Hypercholesterolemia
According to historical estimates, the worldwide preva-
lence of HoFH is 1:1 million [6, 9]. These estimates were
calculated as an extrapolation of a 1973 study of a small
cohort of survivors of myocardial infarction, which esti-
mated the prevalence of HeFH as 1 case per 300–500
people [10]. More recent studies based on the direct
screening of an unselected population in Northern Europe
showed a prevalence of HeFH of 1 in 200, and by
extrapolation, HoFH may affect up to 6 individuals per
million (or 1 in 160,000–300,000) [5].
3 Genetics of Familial Hypercholesterolemia
HoFH is a disease that results from a defect in recycling
cholesterol through the usual LDLR-mediated mechanisms
[11, 12]. Upon binding to apoB, the LDL ligand receptor
complex undergoes receptor-mediated endocytosis (Fig. 2),
thereby reducing serum LDL-C levels. Mutations in LDLR
that prevent apoB binding to LDLR or result in a complete
absence of LDLR protein effectively result in a defective
uptake of LDL-C from the circulation, and, consequently, an
increase in serum LDL-C levels. More than 1700 such
mutations in the LDLR gene have been identified [5].
Less commonly, patients with a clinical HoFH pheno-
type may have mutations in the genes encoding apoB, pro-
protein convertase subtilisin/kexin 9 (PCSK9), or the
LDLR adapter protein 1 (LDLRAP1), which lead to ele-
vations in LDL-C [11, 12]. Mutations in apoB can inhibit
binding to LDLR, thereby causing elevated LDL-C levels
in the blood [13]. The PCSK9 protease binds to the LDL-
LDLR complex targeting it for degradation in lysosomes,
thereby preventing normal recycling of LDLR back to the
cell surface (Fig. 2). Gain-of-function mutations in PCSK9
are thought to constitutively target the LDL-receptor
complex down a degradative pathway [14]. LDLRAP1 is
an adapter protein that binds to clathrin and facilitates the
endocytosis of the LDL-receptor complex (Fig. 2). Loss-
of-function mutations in the LDLRAP1 gene prevent
internalization of the LDL-LDLR complex. These reces-
sive mutations cause a rare form of FH called autosomal
recessive hypercholesterolemia (ARH), a condition
resembling HoFH [15].
Fig. 1 a Interdigital and
b extensor tendon xanthomata
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Regardless of the mutation status, the severity of HoFH
is based on LDL-C levels [6]. There is considerable
heterogeneity in LDL-C levels among HoFH patients
(Fig. 3) resulting from the large number of contributing
mutations and their effects on LDL-C metabolism [6, 16–
23]. Whereas some mutations in the LDLR gene completely
eliminate LDLR function (\2 % of normal activity;
receptor-negative or null mutations), others reduce function
by up to 75 % (2–25 % of normal activity; receptor-de-
fective mutations) [24]. Patients with receptor-negative
HoFH generally have higher levels of LDL-C, respond
poorly to conventional therapy, and have more accelerated
disease than patients with receptor-defective HoFH [25].
Heterogeneity at the molecular level can also result from
the type of mutations on each allele. True homozygous
patients have two identical mutations of the LDLR gene,
whereas compound heterozygous patients (still considered
HoFH) have different mutations on each copy of the LDLR
gene. Very rarely, patients can have mutations on two
different genes (double heterozygous) [24]. Regardless of
the allelic variations, all of these patients would be clini-
cally diagnosed with HoFH [26].
Other confounding factors, such as incomplete pen-
etrance or polymorphisms in other lipid modifier genes,
can also contribute to the genetic heterogeneity
observed in HoFH. Because of the substantial hetero-
geneity in the genetics of the disease, HoFH should be
















Fig. 2 Proteins involved in
lipoprotein metabolism that are
mutated in HoFH. ApoB
apolipoprotein B, LDL low-
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Treatment Goals in HoFH 9:  900-1,000+ 800-900 700-800 600-700 500-600 400-500 300-400 200-300 100-200 0-100 mg/dL 
mmol/L 
aIncludes studies with statins, ezetimibe, niacin, fibrates, cholesterol absorption inhibitors, bile acid sequestrants and apheresis.
<100 mg/dL (<2.5 mmol/L) 
<70 mg/dL (<1.8 mmol/L) for patients with CVD
 LDL-C range for untreated 
HoFH patients
LDL-C range for HoFH patients treated with 
conventional lipid-lowering therapiesa
Mean LDL-C  
In US Adults
Treatment Goals in HoFH 9:  23.2-25.9+ 20.7-23.2 18.1-20.7 15.4-18.1 12.9-15.4 10.4-12.9 7.7-10.4 5.2-7.7 2.6-5.2 0-2.46 
Treatment Goals in HoFH: 
Fig. 3 Range of LDL-C levels reported in HoFH patients in published literature [6, 16–23]. CVD cardiovascular disease, LDL-C low-density
lipoprotein cholesterol, HoFH homozygous familial hypercholesterolemia
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4 Diagnosis of Familial Hypercholesterolemia
According to the National Lipid Association (NLA) [27],
the severe hypercholesterolemia phenotype (which
includes HoFH) should be suspected in the following
patients [9]:
• Children, adolescents, or young adults (\20 years)
with:
• LDL-C C160 mg/dL (C4.1 mmol/L).
• Non-high-density lipoprotein cholesterol (non-
HDL-C) C190 mg/dL (C4.9 mmol/L).
• Adults C20 years with:
• LDL-C C190 mg/dL (C4.9 mmol/L).
• Non-HDL-C C220 mg/dL (5.7 mmol/L).
Historically, the diagnosis of HoFH was based on
untreated LDL-C levels of[500 mg/dL ([12.9 mmol/L)
and treated levels C300 mg/dL (C7.7 mmol/L); in addi-
tion, cutaneous or tendon xanthomas before age 10 and
elevated LDL-C in both parents (suggesting HeFH) were
also considered [7]. However, recently published data have
confirmed that LDL-C levels can overlap between patients
with HeFH and HoFH (Fig. 3) [6]. In two recent studies,
patients with genetically confirmed HoFH had untreated
LDL-C levels \500 mg/dL (\12.9 mmol/L) [16, 28].
Furthermore, with the use of traditional lipid-lowering
agents, treated LDL-C levels of\300 mg/dL (\7.7 mmol/
L) in patients with genetically confirmed HoFH have also
been reported [17, 21]. Thus, diagnosis of HoFH should not
be excluded based on treated LDL-C levels\300 mg/dL
(\7.7 mmol/L), but must also include other supportive
clinical or genetic evidence. In the absence of a clear-cut
definition of HoFH, physicians must make a considered
clinical diagnosis based on LDL-C levels and family his-
tory, as well as severity of ASCVD and response to prior
treatments [26].
Genetic testing, although accurate in making a definitive
diagnosis of HoFH, is not routinely used in clinical prac-
tice, because of limited access to laboratories where these
tests are conducted [6]. Furthermore, a negative genetic test
may not be sufficient to prove absence of disease because
the test may miss a disease-causing mutation. Genetic
mutations that are identified in a patient may, however, be
used to facilitate cascade screening [4, 6, 29]. Because
HoFH is a genetic disease, there is a high likelihood of the
disease being expressed within family members and three
of four first-degree relatives of patients with HoFH likely
have either HeFH or HoFH [30]. Physicians should screen
immediate family members of the proband for risk of FH
by testing with a plasma lipid profile with or without
genetic analysis for the family mutations [4, 6]. If another
patient with FH is identified, first-degree relatives of that
proband should also be screened. The goal of cascade
testing is to reduce morbidity and mortality from ASCVD
by identifying patients early and effectively managing the
condition [4].
All patients diagnosed with HoFH should be assessed
for other risk factors for CAD, as well as the presence of
symptomatic or subclinical atherosclerosis. An assessment
of cholesterol-life years, or cumulative cholesterol burden,
may also be useful in risk assessment [4].
5 Treatment Options for Homozygous Familial
Hypercholesterolemia
5.1 Treatment Goals
There is limited evidence from patients with HoFH to
allow the determination of optimal post-treatment LDL-C
levels. It is also unclear whether goals based on other high-
risk populations, such as patients with FH, are relevant to
the HoFH population, who show massive perturbations in
LDL-C metabolism. In the absence of such clinical evi-
dence, LDL-C targets comparable to those in the nor-
molipidemic population are ideal, but in reality a 50 %
reduction in LDL-C levels is the best that can be achieved
and is a good starting point until further evidence accrues.
Several evidence-based guidelines, chiefly based on
expert opinion, have defined treatment goals for patients
with HoFH. The European Atherosclerosis Society (EAS)
has made HoFH-specific recommendations for target LDL-
C levels of \100 mg/dL (\2.5 mmol/L) in adults or
\70 mg/dL (\1.8 mmol/L) in adults with clinical coro-
nary heart disease (CHD) or diabetes [5, 6]. The EAS
acknowledges, however, that ‘‘such targets are ambitious
and careful evaluation of the benefit vs. risk of therapeutic
options is needed.’’ The panel also notes that because of the
phenotypic and genotypic variations associated with
HoFH, patients may respond differently to lipid-lowering
therapies [6].
Evidence-based guidelines for FH from the NLA rec-
ommend that treatment goals should focus on reducing
LDL-C levels by C50 % from pretreatment levels if target
LDL-C levels cannot be achieved [27, 31]. For high-risk
patients (including HoFH patients), the NLA suggests that
non-HDL-C and LDL-C levels be lowered to\130 mg/dL
(\3.4 mmol/L) and\100 mg/dL (\2.5 mmol/L), respec-
tively. For FH patients with multiple or other poorly con-
trolled risk factors for cardiovascular disease, the NLA
recommends attaining even lower levels of atherogenic
cholesterol [27].
The International FH Foundation recommends that as an
initial goal, therapy should aim for a reduction of C50 % in
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plasma LDL-C levels. In the absence of CHD or other
major risk factors, an LDL-C treatment goal of\100 mg/
dL (\2.5 mmol/L) is recommended, whereas a goal of
\70 mg/dL (\1.8 mmol/L) is suggested for patients with
CHD or other major risk factors [4].
5.2 Lifestyle Modifications
Patients should be counseled to consume a heart-healthy
diet low in saturated fat and cholesterol and encouraged to
participate in appropriate levels of physical activity.
Patients should aggressively control other traditional risk
factors, such as smoking, hypertension, diabetes, and
obesity. Despite these lifestyle modifications, pharmaco-
logic intervention is generally required to reduce non-
HDL-C and LDL-C levels in patients with HoFH [6].
5.3 Conventional Therapies
Several classical treatment options are available for low-
ering lipid levels in patients with HoFH (Table 1). Statins,
the mainstay of therapy, lower LDL-C levels predomi-
nantly by upregulating LDLR. Because patients with HoFH
lack fully functioning LDLR, statins are not generally
effective in this population, in whom only modest reduc-
tions in LDL-C levels of *20 % are observed [32, 33].
The addition of ezetimibe, an inhibitor of cholesterol
absorption, to statins may further lower LDL-C levels by
10–15 % with minimal adverse events while also reducing
the incidence of cardiovascular events [18, 34]. Combining
statins with other drugs, such as bile acid sequestrants or
niacin may also lower LDL-C levels, but the use of these
combinations may be limited by adverse events [6].
Patients with HoFH are frequently refractory to these
conventional lipid-lowering therapies, which rarely lower
LDL-C levels in these patients to the recommended target
goals [6].
Lipoprotein apheresis (LA) is a treatment option avail-
able to some patients with HoFH who cannot tolerate drug
therapy or in whom the drugs are ineffective. A single
treatment can effectively reduce serum LDL-C levels by
between 50 and 70 %. Although LA is repeated every 1 to
2 weeks, LDL-C levels are not consistently maintained
within acceptable limits. LDL-C levels rebound rapidly
after treatment returning to 50 and 90 % of pre-apheresis
levels after 4 and 14 days, respectively [35]. Long-term use
of LA has been reported to promote regression of xan-
thomas, slow the progression of atherosclerosis, and
mediate a marked reduction in the inflammation of arterial
walls that is characteristic of FH [31, 36]. Although LA is
time consuming and not easily available to all HoFH
patients, it may be a cost-effective option for the treatment
of HoFH [4].
Liver transplantation (alone or in combination with a
heart transplant) may be considered for young HoFH
patients, although disadvantages for this approach include
the high risk of post-transplantation complications and
mortality, as well as the limited availability of donors.
Table 1 Mechanisms of actions of lipid-lowering therapies
Lipid-lowering therapy Mechanism of action LDL-lowering response in patients with HoFH
Conventional therapies
Statins Competitively inhibit HMG CoA reductase reducing
endogenous cholesterol synthesis (LDLR up-regulator)
Up to 28 %
Ezetimibe Inhibits cholesterol absorption \10 %
Bile acid sequestrants Decrease reabsorption of bile acids and reduce
cholesterol content in hepatocytes
\10 %
Niacin Decrease VLDL synthesis \10 %
LDL apheresis Removes LDL particles from the circulation using
dextran sulphate or heparin
20–40 %
Novel treatment options
Lomitapide Inhibits microsomal triglyceride transfer protein, thereby
interfering with the assembly of lipoproteins
50 % (in combination with conventional therapies
including LDL apheresis) [17]
Mipomersen Inhibits apoB synthesis 25 % (in combination with conventional therapies




Inhibits PCSK9, which regulates recycling of the LDLR
(LDLR up-regulator)
23 % (for evolocumab in combination with
conventional therapies excluding LDL apheresis)
[49]
HDL high-density lipoprotein, LDL low-density lipoprotein, LDLR low-density lipoprotein receptor, PCSK9 pro-protein convertase subtilisin/
kexin 9, PPARa peroxisome proliferator-activated receptor-alpha, VLDL very-low-density lipoprotein
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Other options, such as partial ileal bypass and portocaval
shunting, are not recommended for this population but may
be considered for patients with very severe disease in
whom other conventional options are not effective [4, 6].
5.4 Other Treatment Options
The EAS has suggested a treatment algorithm showing how
lifestyle modifications can be combined with conventional
pharmacotherapy for the management of HoFH (Fig. 4) [6].
Despite the availability and use of the conventional phar-
macotherapy, only a small proportion of patients with HoFH
achieve the non-HDL-C and LDL-C targets recommended
by the NLA guidelines [27], underscoring the need for novel
treatment options that decrease atherogenic cholesterol
levels beyond those currently achieved. Lomitapide and
mipomersen are approved as adjunct therapy to conventional
lipid-lowering therapies for HoFH in patients C18 and
C12 years, respectively [37, 38]. The two drugs have not
been compared directly in head-to-head studies. Both drugs
have different mechanisms of action, but they effectively
reduce the production and secretion of apoB-containing
lipoproteins. Because of the potential risk for hepatic
toxicity, both lomitapide and mipomersen are restricted for
use in patients with HoFH who are participating in a Risk
Evaluation and Mitigation Strategy (REMS) program [6].
Two PCSK9 inhibitors, evolocumab and alirocumab, have
been recently been approved in the US, evolocumab for the
treatment of HoFH, and alirocumab for the treatment of
patients with clinical atherosclerotic cardiovascular disease
who require additional lowering of LDL-C [39, 40]. Addi-
tional data on long-term safety and efficacy for these prod-
ucts are needed. These long-term data can also be used for
detailed cost/benefit analyses of the novel products for
HoFH,whose prices are consistent with other drugs that have
orphan designations [41].
5.4.1 Lomitapide
Lomitapide is an oral inhibitor of the microsomal triglyc-
eride transport protein (MTP), which transfers triglycerides
and phospholipids onto apoB, thereby playing an important
role in the assembly and secretion of apoB-containing
lipoproteins in the liver and intestines [42]. By inhibiting
MTP, lomitapide induces post-translational degradation of
apoB, thereby reducing the secretion of lipoproteins into
Homozygous Familial Hypercholesterolemia
LDL-C targets:
<2.5 mmol/L [<100 mg/dL] – adults
<3.5 mmol/L [<135 mg/dL] – children
<1.8 mmol/L [<70 mg/dL] if clinical CVD
At Diagnosis
Lifestyle and diet + statin (most effective
at highest dose depending on tolerability)
LDL apheresis
As early as possible if available (by 5 years,
no later than 8 years) every 1 or 2 weeks
Ezetimibe + resins or other drugs
(Fibrate, nicotinic acid, [use of these
additional treatments may be limited by








Fig. 4 Recommended algorithm for management of HoFH (adapted
from Cuchel M, Homozygous familial hypercholesterolaemia: new
insights and guidance for clinicians to improve detection and clinical
management. A position paper from the Consensus Panel on Familial
Hypercholesterolaemia of the European Atherosclerosis Society,
European Heart Journal, 2014, Volume 35, Issue 32, 2146–2157,
by permission of Oxford University Press [6]). CVD cardiovascular
disease, LDL low-density lipoprotein, LDL-C low-density lipoprotein-
cholesterol, PCSK9 pro-protein convertase subtilisin/kexin 9
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the blood, resulting in lower serum cholesterol and
triglyceride levels [42, 43].
In an open-label, dose-escalation study of 29 patients with
HoFH, lomitapide (5 to 60 mg/day) was added to standard of
care including LA [17]. Of the 23 patients who completed
treatment (median lomitapide dose, 40 mg/day),mean LDL-
C, apoB, and lipoprotein(a) levels were reduced by 50 %
(p\ 0.0001), 49 % (p\ 0.0001), and 15 % (p = 0.0003) at
26 weeks. Of the 18 patients on the study who underwent
routine LA, three permanently discontinued the procedure
and another three increased the duration between apheresis
sessions. The LDL-C-lowering effect was durable, with a
reduction of 44 % (p\ 0.0001) and 38 % (p = 0.0001)
observed at weeks 52 and 78, respectively. Similarly, apoB
levels were significantly reduced by 45 % (p\ 0.0001) and
43 % (p\ 0.0001) at these later time points. However, the
effect of lomitapide on lipoprotein(a) levels was not sus-
tained returning to baseline at 78 weeks.
The most common adverse events reported in 93 % of
patients were gastrointestinal in nature [mitigated by
adherence to a low-fat diet (i.e. supplying\20 % of total
energy from fat)], accumulation of liver fat, and elevations
in alanine aminotransaminase levels. Because the cyto-
chrome P450 enzyme, CYP3A4, metabolizes lomitapide,
there is a potential for interaction with even moderate
inhibitors of the enzyme, suggesting that concomitant
administration of the two drugs should be carefully con-
sidered [37]. It should be noted, however, that a phase 1
study showed no clinically relevant increase in lomitapide
exposure with the weak CYP3A4 inhibitors, atorvastatin
and ethinyl estradiol/norgestimate [44].
Long-term follow-up data were collected from 19 of 23
patients who completed the phase 3 trial and entered an
open-label extension study [45]. Patients continued lomi-
tapide treatment at their maximum tolerated dose and 17/19
(89 %) of patients completed at least 126 weeks of treat-
ment at which point LDL-C levels were reduced by 45.5 %
compared with baseline. No new safety signals were
identified during the long-term extension study.
5.4.2 Mipomersen
Mipomersen is an antisense oligonucleotide directed
against the messenger RNA (mRNA) of apoB, the main
protein component of LDL and very-low-density lipopro-
tein (VLDL). By inducing degradation of the apoB mRNA,
mipomersen blocks the synthesis of apoB protein, thereby
reducing secretion of LDL [46].
In a placebo-controlled double-blind trial in 51 patients
with HoFH, mipomersen 200 mg administered once/week
by subcutaneous injection was added to standard lipid-
lowering therapies (excluding lipoprotein apheresis) [21].
When compared to placebo, mean reductions of plasma
LDL-C, apoB, and lipoprotein(a) levels of 25 %
(p = 0.0003), 27 % (p\ 0.0001), and 32 % (p = 0.0013)
were observed at 26 weeks. Common adverse events with
mipomersen included flu-like reactions, injection site
reactions, and elevations in alanine aminotransaminase
levels. Liver fat was not measured in this study, but
increased liver fat content was observed in other trials of
patients with hypercholesterolemia and HeFH [47].
A total of 141 patients treated with mipomersen in three
different trials (including 38 with HoFH) were enrolled in
an open-label, 104-week extension study [48]. Among
patients who completed 2 years of treatment, the mean
change in LDL-C from baseline to week 104 was a
decrease of 28 %. Significant reductions in ApoB and
lipoprotein(a) levels of 31 % (p\ 0.0001) and 17 %
(p\ 0.0001) were also observed at this later time point. It
should be noted, however, that 77/141 (55 %) of patients
discontinued treatment within the first 2 years (43 % due to
treatment-emergent adverse events). No new safety signals
were observed during the long-term extension study.
5.4.3 PCSK9 Inhibitors
PCSK9 is a protein that targets LDLR for degradation.
Inhibitors of PCSK9, both monoclonal antibodies and
small molecule inhibitors, are being evaluated in clinical
trials of patients with FH. Evolocumab, an anti-PCSK9
monoclonal antibody, was approved in July 2015 by the
European Medicines Agency for the treatment of adults
and adolescents aged 12 years and over with HoFH in
combination with other lipid-lowering therapies [39]. A
second PCSK9 inhibitor, alirocumab, has also been
approved in July 2015 by the US Food and Drug Admin-
istration (FDA) as an adjunct to diet and maximally tol-
erated statin therapy for adult patients with HeFH or
clinical ASCVD, who need additional lowering of LDL
cholesterol [40].
The safety and efficacy of evolocumab was evaluated in
TESLA (Trial Evaluating PCSK9 Antibody in Subjects
With LDL Receptor Abnormalities), a phase 3 randomized,
double-blind trial in 49 patients with HoFH who were not
on LA [49]. The patients were randomized to evolocumab
(n = 33) or placebo (n = 16). Overall, evolocumab
administered subcutaneously at a dose of 420 mg every
4 weeks reduced LDL-C levels by 23.1 % from baseline
and 30.9 % compared with the placebo arm, and lipopro-
tein(a) levels were reduced by 11.8 % from baseline. It
should be noted, however, that the mean LDL-C levels in
patients treated with evolocumab were 7.1 mmol/L
(275 mg/dL), suggesting that combinations of PCSK9
inhibitors with newer agents, such as lomitapide or
mipomersen, have the potential to further lower LDL-C
levels in patients with HoFH.
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The response to evolocumab was dependent on LDLR
status and patients with receptor-defective mutations on
either one (n = 20) or both alleles (n = 8) showed a mean
reduction in LDL-C levels of 40.8 and 46.9 % compared
with placebo. One patient with LDLR-negative mutations
on both alleles and one patient with ARH did not respond
to evolocumab; a slight increase in LDL-C levels compared
with baseline was observed [49]. Similar results were
observed in preclinical studies using human dermal
fibroblasts isolated from receptor-defective (n = 9) and
receptor-negative (n = 4) HoFH patients exposed to alir-
ocumab. In cells incubated with mevastatin (to upregulate
LDLR) followed by recombinant PCSK9 with or without
the antibody, alirocumab restored cell surface expression of
LDLR in cells from receptor-defective HoFH patients,
whereas LDLR expression in cells from receptor-negative
patients was almost undetectable [50].
The most common adverse events with evolocumab
were infections of the upper respiratory tract, influenza,
gastroenteritis and nasopharyngitis, which are relatively
common with monoclonal antibody drugs.
5.5 Future Options
Several other novel options for the treatment of HoFH,
such as gene therapy, are also being investigated. Gene
therapy is a strategy used to correct defective genes
responsible for the development of disease. For example,
replacement of the LDLR gene has the potential to decrease
LDL-C levels while also making patients with HoFH more
responsive to conventional therapies [6]. Preclinical studies
using mouse models of HoFH and HeFH have yielded
promising results [51]. Additional studies and clinical trials
of these gene replacement strategies are warranted.
6 Conclusion
HoFH is a rare disorder of cholesterol metabolism that is
underdiagnosed and undertreated. Evidence in the pub-
lished literature demonstrates that patients with HoFH can
benefit from early diagnosis and treatment. Diagnosis
should be based on a comprehensive evaluation of clinical
criteria and should not be exclusively based on LDL-C
levels because of the wide range of LDL-C levels observed
among untreated and treated patients. This variability in
LDL-C levels can be attributed, at least in part, to the
genetic heterogeneity of the disease. However, the degree
of LDL-C elevation can reflect the efficacy of baseline
treatment and provides the best index for the need for
additional and more aggressive treatment(s). While genetic
testing can provide a definitive diagnosis for some HoFH
patients, many patients may not be identified because of the
high false-negative rate, as well as the absence of validated
tests for all mutations that may cause the disease.
Early detection and aggressive intervention with statins
in combination with other lipid-lowering agents, along with
lipoprotein apheresis, is generally recommended for HoFH
patients. However, the combination of these agents and
procedures cannot usually bring LDL-C levels to the rec-
ommended treatment goals. Recently approved agents,
such as lomitapide, mipomersen, and evolocumab have
shown efficacy in further reducing LDL-C levels in
patients with HoFH. Patients with HoFH need access to
these novel non-statin agents to help control their LDL-C
levels. The impact of these new treatments on cardiovas-
cular events has not been determined and needs evaluation.
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